Phase III trial comparing doxorubicin docetaxel (AT) with doxorubicin cyclophosphamide (AC) in the adjuvant treatment of high-risk node negative (pNO) and limited node positive (pN+≤53) breast cancer (BC) patients (pts):: First analysis of toxicity.

被引：0
|
作者：
Brain, EGC
Bachelot, T
Serin, D
Graïc, Y
Eymard, JC
Extra, JM
Combe, M
Nogues, C
Rouëssé, J
机构：
[1] Ctr Rene Huguenin, St Cloud, France
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Inst St Catherine, Avignon, France
[4] Ctr Henri Becquerel, F-76038 Rouen, France
[5] Inst Jean Godinot, Reims, France
[6] Inst Curie, F-75231 Paris, France
[7] Le Mans Hosp, Le Mans, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
617
引用
收藏
页码：31S / 31S
页数：1
相关论文
共 50 条
  • [1] Final results of the RAPP-01 phase III trial comparing doxorubicin and docetaxel with doxorubicin and cyclophosphamide in the adjuvant treatment of high-risk node negative and limited node positive (≤3) breast cancer patients.
    Brain, E. G.
    Debled, M.
    Eymard, J-C
    Bachelot, T.
    Extra, J-M
    Serin, D.
    Combe, M.
    Fourme, E.
    CANCER RESEARCH, 2009, 69 (02) : 280S - 281S
  • [2] E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer.
    Goldstein, LJ
    O'Neill, A
    Sparano, J
    Perez, E
    Shulman, L
    Martino, S
    Davidson, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 7S - 7S
  • [3] A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Yardley, Denise A.
    Burris, Howard A., III
    Farley, Cindy P.
    Barton, John H.
    Peacock, Nancy W.
    Spigel, David R.
    Greco, F. Anthony
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2008, 8 (03) : 242 - 248
  • [4] BCIRG 005 main efficacy analysis: a phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC → T) in women with Her-2/neu negative axillary lymph node positive early breast cancer.
    Eiermann, W.
    Pienkowski, T.
    Crown, J.
    Chap, L.
    Pawlicki, M.
    Martin, M.
    Saleh, M.
    Sehdev, S.
    Provencher, L.
    Von Minckwitz, G.
    Semiglazov, V
    Slamon, D.
    Tabah-Fish, I
    Buyse, M.
    Riva, A.
    Taupin, H.
    Sauter, G.
    Mackey, J.
    CANCER RESEARCH, 2009, 69 (02) : 82S - 82S
  • [5] Phase II randomized adjuvant trial of dose-dense docetaxel (DOC) before or after doxorubicin/cyclophosphamide (AC) in axillary node-positive breast cancer.
    Puhalla, S.
    Young, D.
    Ottman, S.
    McVey, A.
    Kendra, K.
    Mrozek, E.
    Rhodes, C.
    Merriman, N. J.
    Knapp, M.
    Patel, T.
    Thompson, M. E.
    Maher, J. F.
    Moore, T. D.
    Shapiro, C. L.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S115 - S116
  • [6] A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel plus sorafenib in women with node positive or high-risk breast cancer.
    Spigel, D. R.
    Molthrop, D.
    Peacock, N.
    Kommor, M.
    Markus, T.
    Vazquez, E.
    Greco, F. A.
    Burris, H. A.
    Hainsworth, J. D.
    Yardley, D. A.
    CANCER RESEARCH, 2009, 69 (02) : 190S - 190S
  • [7] ANALYSIS OF THE TOXICITY AND TOLERABILITY IN ADJUVANT VINORELBINE AND EPIRUBICINE VERSUS DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR TREATING NODE NEGATIVE BREAST CANCER; RANDOMIZED PHASE II TRIAL [AVIEN STUDY]
    Kim, K. S.
    ANNALS OF ONCOLOGY, 2012, 23 : 15 - 16
  • [8] Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients:: BCIRG 006 study
    Slamon, D
    Eiermann, W
    Robert, N
    Pienkowski, T
    Martin, M
    Pawlicki, M
    Chan, A
    Smylie, M
    Liu, M
    Falkson, C
    Pinter, T
    Fornander, T
    Shiftan, T
    Valero, V
    Von Minckwitz, G
    Mackey, J
    Tabah-Fisch, J
    Buyse, M
    Lindsay, MA
    Riva, A
    Bee, V
    Pegram, M
    Press, M
    Crown, J
    BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S5 - S5
  • [9] A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer
    Loesch, D. M.
    Greco, F.
    O'Shaughnessy, J.
    Hainsworth, J. D.
    Vukelja, S. J.
    Sandbach, J.
    Boehm, K. A.
    Ilegbodu, D.
    Asmar, L.
    Robert, N. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Docetaxel/capecitabine (TX) vs. doxorubicin/cyclophosphamide (AC) as primary chemotherapy for patients (pts) with stage II/III breast cancer (BC): interim analysis findings from a phase III randomised trial
    不详
    BREAST, 2005, 14 : S40 - S40
12345